Warren Buffett has been on a selling spree
Through Berkshire Hathaway…Warren Buffett recently dumped $800 million of Apple stock…

And bought this instead!

He’s now moved $3.8 BILLION in a tiny niche of the tech sector billionaires are flocking to…
Click to see what Buffett knows

NVUS Insider Trading (Novus Therapeutics)

Insider Ownership Percentage: 2.20%
Insider Buying (Last 12 Months): $2,341,497.60
Insider Selling (Last 12 Months): $2,229,120.00

Novus Therapeutics Insider Trading History Chart

Novus Therapeutics Share Price & Price History

$16.07
▼ -0.43 (-2.61%)
As of 02/26/2021 01:00 AM ET
Days: 30 | 90 | 365
The DOW is Dead - This Could be Your Last Chance to “Crash Proof”
I've been preparing for this moment for five years.

The fact is, I'd hoped this day would never come...
Click here to see why

Novus Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/2/2020Israel Gp Ltd. OrbimedMajor ShareholderSell103,200$21.60$2,229,120.00  
10/30/2020Logos Global Management LpMajor ShareholderBuy92,040$25.44$2,341,497.60  
5/21/2019Catherine C TurkelPresidentSell9,537$1.95$18,597.1590,576  
5/21/2019Gregory J FlesherCEOSell14,638$1.95$28,544.10159,855  
5/21/2019Jon KuwaharaInsiderSell5,276$1.95$10,288.207,032  
5/2/2019Erez ChimovitsDirectorBuy646,204$3.10$2,003,232.40  
4/30/2019Lifesci Index Partners LlcMajor ShareholderSell200$2.70$540.00  
9/12/2018Catherine C TurkelPresidentBuy33,680$4.78$160,990.4061,567  
9/5/2018Catherine C TurkelPresidentBuy805$3.97$3,195.8544,519  
See Full Table

SEC Filings (Institutional Ownership Changes) for Novus Therapeutics (NASDAQ:NVUS)

Institutional Buying and Selling by Quarter

Novus Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in Company
2/16/2021Orbimed Advisors LLC73,650$1.11M0.0%-97.7%5.129%
2/12/2021Stonepine Capital Management LLC167,333$2.58M2.0%N/A11.653%
2/11/2021Asymmetry Capital Management L.P.80,069$1.23M0.6%-92.6%5.576%
2/10/2021Renaissance Technologies LLC43,251$0.67M0.0%-94.3%3.012%
2/5/2021BlackRock Inc.10,714$0.17M0.0%+66.5%0.746%
11/11/2020Thrivent Financial for Lutherans45,761$43K0.0%N/A4.245%
11/9/2020Acadian Asset Management LLC170,176$0.16M0.0%+57.3%15.786%
8/14/2020BVF Inc. IL1,785,000$0.82M0.1%+160.7%11.108%
8/7/2020Virtu Financial LLC92,113$42K0.0%N/A0.573%
2/13/2020Renaissance Technologies LLC455,736$0.26M0.0%+19.2%3.515%
8/17/2019Orbimed Advisors LLC3,183,314$3.22M0.0%+25.5%24.525%
8/14/2019Citadel Advisors LLC39,647$40K0.0%N/A0.306%
8/14/2019Vanguard Group Inc.270,160$0.27M0.0%+528.2%2.082%
8/13/2019BlackRock Inc.33,544$34K0.0%+69.2%0.259%
8/5/2019National Asset Management Inc.270,000$0.27M0.0%+69.1%2.081%
5/8/2019National Asset Management Inc.159,705$0.64M0.1%+32.8%1.693%
5/6/2019Seelaus Asset Management LLC10,000$40K0.0%N/A0.106%
4/1/2019Deutsche Bank AG50,846$81K0.0%-30.3%0.539%
2/8/2019National Asset Management Inc.120,219$0.19M0.0%+167.2%1.276%
12/13/2018Vanguard Group Inc135,599$0.63M0.0%+73.5%1.439%
11/23/2018Vanguard Group Inc.135,599$0.63M0.0%+73.5%1.439%
11/13/2018Renaissance Technologies LLC251,556$1.18M0.0%+28.6%2.670%
11/8/2018National Asset Management Inc.45,000$0.21M0.0%+345.9%0.478%
8/13/2018Renaissance Technologies LLC195,588$1.37M0.0%+78.0%2.076%
5/21/2018Derby & Company Inc.29,545$0.15M0.1%+60.3%0.314%
2/15/2018Lyon Street Capital LLC338,929$1.38M0.5%+102.3%4.780%
11/14/2017Lyon Street Capital LLC167,577$0.87M0.3%+311.1%2.364%
8/14/2017Lyon Street Capital LLC40,766$0.24M0.1%N/A5.509%
Data available starting January 2016

See Full Table
Novus Therapeutics logo
Novus Therapeutics, Inc., a specialty pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is OP0201, a surfactant-based nasal aerosol drug-device combination product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). The company also has a foam-based drug delivery technology OP0101 and OP0102 that could be used to deliver drugs into the ear, nose, and sinus cavities. Novus Therapeutics, Inc. is headquartered in Irvine, California.
Read More

Today's Range

Now: $16.07
$15.81
$16.49

50 Day Range

MA: $15.95
$14.25
$19.22

52 Week Range

Now: $16.07
$4.50
$27.32

Volume

104,309 shs

Average Volume

78,851 shs

Market Capitalization

$23.08 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.07

Who are the company insiders with the largest holdings of Novus Therapeutics?

Novus Therapeutics' top insider investors include:
  1. Gregory J Flesher (CEO)
  2. Catherine C Turkel (President)
  3. Jon Kuwahara (Insider)
  4. Erez Chimovits (Director)
  5. Israel Gp Ltd Orbimed (Major Shareholder)
  6. Lifesci Index Partners Llc (Major Shareholder)
  7. Logos Global Management Lp (Major Shareholder)

Who are the major institutional investors of Novus Therapeutics?

Novus Therapeutics' top institutional investors include:
  1. Stonepine Capital Management LLC — 11.65%
  2. Asymmetry Capital Management L.P. — 5.58%
  3. Orbimed Advisors LLC — 5.13%
  4. Renaissance Technologies LLC — 3.01%
  5. BlackRock Inc. — 0.75%

Which institutional investors are selling Novus Therapeutics stock?

During the last quarter, NVUS stock was sold by these institutional investors:
  1. Orbimed Advisors LLC
  2. Asymmetry Capital Management L.P.
  3. Renaissance Technologies LLC

Which institutional investors are buying Novus Therapeutics stock?

During the previous quarter, NVUS stock was bought by institutional investors including:
  1. Stonepine Capital Management LLC
  2. BlackRock Inc.
Within the last year, these company insiders have bought Novus Therapeutics stock:
  1. Gregory J Flesher (CEO)
  2. Catherine C Turkel (President)
Warren Buffett has been on a selling spree
Through Berkshire Hathaway…Warren Buffett recently dumped $800 million of Apple stock…

And bought this instead!

He’s now moved $3.8 BILLION in a tiny niche of the tech sector billionaires are flocking to…
Click to see what Buffett knows